Search

Displaying results 1351 - 1360 of 1723 in total
  1. Drug

    Romosozumab

    go.drugbank.com/drugs/DB11866
    ApprovedInvestigational

    Romosozumab was granted FDA approval on April 9,2019[L5921].

  2. Drug

    Gadoxetic acid

    go.drugbank.com/drugs/DB08884
    ApprovedInvestigational

    [A263146] Gadoxetic acid, under the form gadoxetate disodium, is marketed by Bayer HealthCare Pharmaceuticals under the brand name EOVIST and FDA approved in 2008.[A263151]

  3. Drug

    Obinutuzumab

    go.drugbank.com/drugs/DB08935
    ApprovedInvestigational

    [L54521] First approved by the FDA on February 26, 2016,[L54531] obinutuzumab is used to treat chronic lymphocytic leukemia, follicular lymphoma, and lupus nephritis.[L54521]

  4. Drug

    Copper histidinate

    go.drugbank.com/drugs/DB32041
    Approved

    It was approved by the US FDA in January 2026 for the treatment of pediatric patients with Menkes disease.[L54993,L54998]

  5. Drug

    Valproic acid

    go.drugbank.com/drugs/DB00313
    ApprovedInvestigational

    It first received approval on February 28, 1978 from the FDA under the trade name Depakene.[L6190] Since then, it has been investigated for neuroprotective, anti-manic, and anti-migraine effects.

  6. Drug

    Pizotifen

    go.drugbank.com/drugs/DB06153
    Approved

    Sandomigran is available in a number of countries but is not approved by the FDA nor EMA.

  7. Drug

    Methacholine

    go.drugbank.com/drugs/DB06709
    Approved

    [A229648, L31763] Methacholine was granted FDA approval on October 31, 1986, and is marketed under the trademark PROVOCHOLINE® by Methapharm Inc.[L31763]

  8. Drug

    Brexpiprazole

    go.drugbank.com/drugs/DB09128
    ApprovedInvestigational

    [A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015.

  9. Drug

    Nifurtimox

    go.drugbank.com/drugs/DB11820
    ApprovedInvestigational

    On August 6 2020, accelerated FDA approval was granted for its use in pediatric patients in response to promising results from phase III clinical trials.

  10. Drug

    Deflazacort

    go.drugbank.com/drugs/DB11921
    Approved

    It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.